Cognition Therapeutics (CGTX) Income from Continuing Operations (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Income from Continuing Operations of 8867000.0 for Q1 2026, up 35.89% year-over-year from 6525111.84 in Q1 2025, and up 35.4% quarter-over-quarter from 13726000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Income from Continuing Operations for 7 consecutive years, with 8867000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 35.89% year-over-year to 8867000.0; the TTM figure through Mar 2026 stood at 43849000.0 (up 21.04% YoY), while the FY2025 annual figure was 83825000.0, down 146.75% from the prior year.
- Income from Continuing Operations rose to 8867000.0 in Q1 2026 per CGTX's latest filing, from 13726000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3838000.0 in Q1 2022 and bottomed at 15799000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 11338588.24 across 5 years, with a median of 13726000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 1821.08% — and 2025, when it surged 55.05%.
- Cognition Therapeutics' Income from Continuing Operations stood at 12262000.0 in 2022, then fell by 24.32% to 15244000.0 in 2023, then rose by 29.29% to 10779000.0 in 2024, then dropped by 27.34% to 13726000.0 in 2025, then surged by 35.4% to 8867000.0 in 2026.
- Business Quant data shows CGTX's Income from Continuing Operations at 8867000.0 in Q1 2026, 13726000.0 in Q4 2025, and 6799000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -7.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.35 Mn |
| Mar 31, 2026 | -8.87 Mn |
| Dec 31, 2025 | -13.73 Mn |
| Sep 30, 2025 | -6.80 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -13.83 Mn |
| Dec 31, 2024 | -10.78 Mn |
| Sep 30, 2024 | -15.13 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Mar 31, 2024 | -15.62 Mn |
| Dec 31, 2023 | -15.24 Mn |
| Sep 30, 2023 | -15.49 Mn |
| Jun 30, 2023 | -4.73 Mn |
| Mar 31, 2023 | -6.17 Mn |
| Dec 31, 2022 | -12.26 Mn |
| Sep 30, 2022 | -14.28 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.84 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -27.44 Mn |